Promising research trials surrounding Retatrutide , specifically the 120 milligram formulation branded as ZPHC, reveal a significant effect on weight loss and linked health conditions . Researchers posit that this dual agonist , targeting both GLP-1 and GIP receptors , has the potential to represent a noteworthy breakthrough in the management of o